Answers are grounded in this paper and cite their sources.
BACKGROUND AND OBJECTIVES: Dysregulation in the homeostasis of the cytokine pool induces severity in COVID-19 disease, which may result in poor clinical outcomes in severely ill patients. The main objective of this study was to evaluate serum interleukin-6 (IL-6), IL-17A, and interferon-α (IFN-α) in hospitalized COVID-19 patients and its association with the disease severity and clinical outcome. MATERIALS AND METHODS: Fifty-one hospitalized COVID-19 patients and 30 age- and sex-matched healthy volunteers were enrolled in this study. Serum IL-6, IL-17A, and IFN-α were quantified by enzyme-linked immunosorbent assay-based method. Receiver operating characteristic curve (ROC) analysis was performed for the cytokines. RESULTS: Serum IL-6, IL-17A, and IFN-α were significantly higher in COVID-19 patients than healthy control volunteers. Across severity groups, serum IL-6 was significantly higher in the severe group, whereas IFN-α was significantly higher in the mild–moderate group. Serum IL-6 was significantly higher in the deceased group compared to the recovered group. ROC analysis suggests that serum IL-6 can be used as a diagnostic and prognostic marker for severity and clinical outcome, respectively. CONCLUSION: Elevated levels of serum IL-6, IL-17A, and IFN-α in COVID-19 patients indicate cytokine dysregulation following severe acute respiratory syndrome coronavirus 2 infection. Elevated serum IL-6 was associated with disease severity and poor clinical outcome. Elevated IFN-α in mild–moderate group compared to the severe group signifies the antiviral effect of IFN-α may help in limiting disease severity in COVID-19 disease. Our data suggest that IL-6 can be used as a diagnostic and prognostic marker for disease severity and clinical outcome, respectively.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: